Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.30 |
| ▸ | SCD | O00767 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5596727 | 0.85 | SCN9A (0.39) | OPRM1OPRD1OPRK1OPRL1JAK2 | |
| SCHEMBL5596820 | 0.85 | OPRM1 (0.34) | OPRM1OPRD1OPRK1OPRL1JAK2 | |
| SCHEMBL5415547 | 0.83 | HTR2C (0.44) | OPRM1OPRD1OPRK1OPRL1SCD | |
| SCHEMBL5596752 | 0.82 | PTPN11 (0.34) | OPRM1OPRD1OPRK1OPRL1SCD | |
| SCHEMBL5596802 | 0.81 | OPRM1 (0.31) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL5596795 | 0.79 | HTR2C (0.44) | — | |
| SCHEMBL5596986 | 0.78 | C5AR1 (0.39) | ALDH1A1 | |
| SCHEMBL5596631 | 0.78 | GPBAR1 (0.36) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL5596782 | 0.77 | HTR2C (0.43) | — | |
| SCHEMBL5596735 | 0.77 | HSD11B1 (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | MYO1B, CHRM1, MYL12A | OPRM1 691/4885OPRD1 706/4885OPRK1 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.